News & Updates
Filter by Specialty:
Olaparib-abiraterone combo improves PFS in mCRPC
16 Mar 2022
byRoshini Claire Anthony
The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.
Olaparib-abiraterone combo improves PFS in mCRPC
16 Mar 2022Transgender people less likely to undergo cancer screening
15 Mar 2022
Despite being at increased risk for breast and cervical cancer, transgender people experience inequalities in the uptake of routine cancer screening, a study has found.